Significant Contract Modifications ($10M+) — August 01, 2026

Regeneron won a $695.7M cost-plus-fixed-fee contract from HHS/BARDA, with a 10-year performance period through 2027. The cost-plus structure minimizes profit volatility, and the full-and-open competition signals a competitive win, providing a stable revenue stream of ~$69.6M annually.

AT&T's $261.1M delivery order for telephone systems at foreign posts ended in March 2021, but the State Department's continued investment in diplomatic communications infrastructure could lead to recompetes or follow-on contracts, offering a potential catalyst for AT&T's federal segment.

The $695.7M BARDA contract has a vague description ('IGF::OT::IGF') and a 10-year performance period, creating uncertainty around specific deliverables and milestones. Execution risk is elevated despite the cost-plus pricing structure.

The Regeneron contract, awarded in 2017, has only $238.8M outlaid of $695.7M total, indicating slower-than-expected funding. Future outlays could be delayed by continuing resolutions or budget reallocations, impacting revenue recognition.

Regeneron's $695.7M award represents 71% of the total stream value, making the digest's signals heavily reliant on one contractor and one civilian agency. Defense-related contracts are all historical, offering no current revenue, reducing actionable defense insights.

BARDA's consistent funding for biodefense and pandemic preparedness could lead to additional contract modifications or new awards for Regeneron, especially if the government continues to invest in medical countermeasures.

The State Department's investment in telephone systems at foreign posts suggests ongoing infrastructure needs. AT&T or other telecom providers could win follow-on contracts as the department modernizes its communications networks.

The $695.7M Regeneron contract from HHS/BARDA underscores the government's commitment to biodefense and pandemic preparedness, representing 71% of the total stream value. This is a civilian agency award, but it highlights a growth area for biotech firms with BARDA relationships.

The three defense-related contracts (AT&T and Lockheed Martin) are all completed, with no ongoing revenue. They reflect historical spending patterns rather than current defense priorities, limiting their utility for forward-looking defense investment decisions.

{"entity" => "Regeneron Pharmaceuticals", "reason" => "The $695.7M BARDA contract is the highest-materiality award, but only $238.8M has been outlaid, indicating slow funding. Future outlays and potential modifications will be key to revenue visibility.", "trigger" => "Quarterly outlay reports from USASpending.gov; any BARDA contract modifications or option exercises"}

{"entity" => "AT&T", "reason" => "The completed $261.1M State Department contract may lead to follow-on opportunities as the department modernizes foreign post communications.", "trigger" => "State Department solicitation announcements for telecommunications services"}

{"entity" => "Lockheed Martin", "reason" => "The two NASA contracts are historical, but Lockheed's incumbency in NASA R&D could lead to new awards, especially in defense-related aerospace engineering.", "trigger" => "NASA Ames Research Center re-competes for PISCES or similar programs"}